**Supplementary tables**:

**Table S1:** Primary and secondary antibodies used in Western Blot assays.

| Antibody | Supplier | Reference |
|---|---|---|
| Anti-PCSK9 | Abcam | Ab181142 |
| Anti-TLR4 | Santa Cruz Biotech. | Sc-293072 |
| Anti-P-p38 (Thr180/Tyr182) | Cell Signaling | #4511 |
| Anti-p38 | Cell Signaling | #8690 |
| Anti-vinculin | Cell signaling | #18799 |
| Anti-caspase-1 p10 | Cell Signaling | #3866 AF4022 |
| Anti-cleaved caspase-3 | Cell Signaling | #9664 |
| Anti-IκB-α | Cell Signaling | #9242 |
| Anti-P-IκB-α (Ser32) | Cell Signaling | #2859 |
| Anti-P-p65 (Ser536) | Cell Signaling | #3033 |
| Anti-p65 | Cell Signaling | #8242 |
| Anti-β-actin | Sigma | A5441 |
| Anti-rabbit IgG | Bio-Rad | #1706515 |
| Anti-mouse IgG | Sigma | A-4416 |
| Anti-goat IgG | Sigma | A-5420 |

**Table S2.** Specific primer sequences used in qRT-PCR assay (sequences; 5′–3′).

| Gen | Forward | Reverse |
|---|---|---|
| Human primer sequences | | |
| ***ABCA1*** | ACCCACCCTATGAACAACATGA | GAGTCGGGTAACGGAAACAGG |
| ***ABCG1*** | CGTGCGCTTTGTGCTGTTT | CCACTGTAGGTACGTGGGGAT |
| ***CD36*** | CTTTGGCTTAATGAGACTGGGAC | GCAACAAACATCACCACACCA |
| ***CYBB*** | ACCGGGTTTATGATATTCCACCT | GATTTCGACAGACTGGCAAGA |
| ***FASN*** | AAGGACCTGTCTAGGTTTGATGC | TGGCTTCATAGGTGACTTCCA |
| ***HMGCR*** | TGATTGACCTTTCCAGAGCAAG | CTAAAATTCGCATTCCACGAGC |
| ***IL1B*** | TCGAGGCACAAGGCACAACAGG | GCCATGGCTGCTTCAGACACTTGA |
| ***ITGAM*** | GCCTTGACCTTATGTCATGGG | CCTGTGCTGTAGTCGCACT |
| ***LDLR*** | TCTGCAACATGGCTAGAGACT | TCCAAGCATTCGTTGGTCCC |
| ***NLRP3*** | GATCTTCGCTGCCATCAACAG | CGTGCATTATCTGAACCCCAC |
| ***PCSK9*** | GGACTCCTCTGTCTTTGCCC | TCCCGGTGGTCACTCTGTAT |
| ***SREBP1*** | CGCAACCATCTTGGCAACAGT | CGCTTCTCAATGGCGTTGT |
| ***TNF*** | GAGGCCAAGCCCTGGTATG | CGGGCCGATTGATCTCAGC |
| ***36B4*** | GGATTACACCTTCCCACTTGC | GCCACAAAGGCAGATGGATCA |
| Mouse primer sequences | | |
| ***Il1b*** | AGAAGCTGTGGCAGCTACCTG | GGAAAAGAAGGTGCTCATGTCC |
| ***Pcsk9*** | GCCCATCGGGAGATTGAGG | TTCCCTTGACAGTTGAGCACA |
| ***Tnf*** | CATCTTCTCAAAATTCGAGTGACAA | TGGGAGTAGACAAGGTACAACCC |
| ***36b4*** | ACTGGTCTAGGACCCGAGAAG | TCCCACCTTGTCTCCAGTCT |

**Supplementary figures**:




***Figure* S1*. Intracellular content of PCSK9 and mRNA levels of Pcsk9 in murine tissues***. (**A**) Quantification of PCSK9 in different murine tissues. Mice were fed ad libitum and tissues and cells were prepared, homogenized and the protein levels were determined by Western blot. (**B**) Determination of mRNA levels of *Pcsk9* in the corresponding samples analyzed in panel A. Results show a representative blot (A) or the mean ± SD of the corresponding mRNA levels of 6 independent preparations, using *36b4* as internal control, and referencing hepatocyte content.




**Figure S2.** ***Effect of PCSK9 on the production of ROS and proinflammatory cytokines in elicited peritoneal macrophages from wild-type (WT), Ldlr$^{-/-}$ and Tlr4$^{-/-}$ mice.*** (**A-B**) Peritoneal macrophages from the indicated mice genotypes were treated for 18h with 1 µg/ml of recombinant PCSK9. The oxidation of DCFH was measured as an indication of ROS synthesis. (**C**) The mRNA levels of *Tnf* and *Il1b*, and (**D**) the release of TNF-α and IL-1β to the culture medium were determined in peritoneal macrophages from mice of the indicated genotype treated for 4h with 1 µg/ml of recombinant PCSK9. Data show the mean ± SD of macrophages from 5 mice of each genotype, assayed per triplicate. *P<0.05; ***P<0.001 *vs*. the corresponding condition in the absence of PCSK9. $^{\#}$P<0.05; $^{\#\#}$P<0.005; $^{\#\#\#}$P<0.001 *vs*. the corresponding WT counterparts.